Harvard Apparatus Regenerative Technology (HRGN) 10-Q 13 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document Information [Line Items]
Entity Registrant Name	Harvard Apparatus Regenerative Technology, Inc.
Entity Central Index Key	1563665
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	HART
Entity Common Stock, Shares Outstanding		10,128,391
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$12,164	$5,272
Related party receivables	4	27
Other non-trade receivables	0	5
Raw material inventory	212	207
Prepaid expenses	269	317
Total current assets	12,649	5,828
Property, plant and equipment, net of accumulated depreciation of $724 and $611, respectively	1,269	1,376
Total non-current assets	1,269	1,376
Total assets	13,918	7,204
Current liabilities:
Accounts payable	261	370
Related party payable	14	16
Accrued and other current liabilities	399	324
Total current liabilities	674	710
Total non-current liabilities	0	0
Total liabilities	674	710
Commitments and contingencies (note 7)
Stockholders' equity:
Convertible preferred stock, par value $0.01 per share, 2,000,000 shares authorized; 695,857 and 0 shares issued and 671,321 and 0 outstanding, respectively	5,168	0
Common stock, par value $0.01 per share, 30,000,000 shares authorized; 10,069,676 and 7,856,607 shares issued and outstanding, respectively	101	79
Additional paid-in capital	23,641	19,449
Accumulated deficit	-15,658	-13,035
Accumulated other comprehensive (loss), income	-8	1
Total stockholders' equity	13,244	6,494
Total liabilities and stockholders' equity	$13,918	$7,204

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	10,069,676	7,856,607
Common stock, shares outstanding	10,069,676	7,856,607
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$724	$611
Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	695,857	0
Preferred stock, shares outstanding	671,321	0

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues	$0	$23
Cost of revenues	0	12
Gross profit	0	11
Operating expenses:
Research and development	1,182	1,217
Sales and marketing	107	76
General and administrative	1,331	1,724
Total operating expenses	2,620	3,017
Operating loss	-2,620	-3,006
Other expense, net	-3	0
Loss before income taxes	-2,623	-3,006
Income taxes	0	0
Net loss	-2,623	-3,006
Basic and diluted net loss per share (in dollars per share)	($0.30)	($0.39)
Weighted average common shares, basic and diluted (in shares)	8,873	7,760
Comprehensive loss:
Net loss	-2,623	-3,006
Foreign currency translation adjustments	-9	-3
Total comprehensive loss	($2,632)	($3,009)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows used in operating activities:
Net loss:	($2,623)	($3,006)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	738	1,176
Depreciation	112	56
Changes in operating assets and liabilities:
Decrease in related party receivables	23	7
Decrease in non-trade receivables	5	0
Increase in inventories	-5	-91
Decrease in prepaid expenses	48	72
(Decrease) increase in accounts payable	-109	162
(Decrease) increase in related party payable	-2	72
Increase in accrued and other current liabilities	126	143
Net cash used in operating activities	-1,687	-1,409
Cash flows used in investing activities:
Additions to property, plant and equipment	-6	-242
Net cash used in investing activities	-6	-242
Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net	5,357	0
Proceeds from issuance of common stock, net	3,237	247
Net cash provided by financing activities	8,594	247
Effect of exchange rate changes on cash	-9	3
Net increase (decrease) in cash	6,892	-1,401
Cash at the beginning of the period	5,272	14,008
Cash at the end of the period	$12,164	$12,607

Overview_and_Basis_of_Presenta

Overview and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]		1	Overview and Basis of Presentation
	Overview
	Harvard Apparatus Regenerative Technology, Inc. (“HART” or the “Company”) is engaged in the development and commercialization of regenerated organs for human transplant. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.
	HART was incorporated in Delaware on May 3, 2012 by Harvard Bioscience Inc. (“Harvard Bioscience”), as a wholly-owned subsidiary, to provide a means for separating Harvard Bioscience’s regenerative medicine business from its other businesses.
	On October 31, 2013, Harvard Bioscience contributed its regenerative medicine business assets, plus $15 million of cash, into HART (the “Separation”). On November 1, 2013, the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience stockholders of all the shares of common stock of HART (the “Distribution”).
	Basis of Presentation
	Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred.
	The financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”).
	Unaudited Interim Financial Information
	The accompanying interim balance sheet as of March 31, 2015 and consolidated statements of operations and comprehensive loss for the three months ended March 31, 2015 and 2014 are unaudited. The accompanying interim consolidated statements of cash flows for the three months ended March 31, 2015 and 2014 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2015, its results of operations for the three months ended March 31, 2015 and 2014, and the Company’s consolidated statements of cash flows for the three months ended March 31, 2015 and 2014.  The financial data and other information disclosed in these notes related to the three month periods ended March 30, 2015 and 2014 are unaudited. The results for the three months ended March 31, 2015 and 2014 are not necessarily indicative of results to be expected for the year ending December 31, 2015, any other interim periods or any future year or period.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]		2	Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements
	The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the financial statements for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K.
	There are no other recently issued accounting standards that are not yet effective that the Company believes would materially impact the financial statements.

Capital_Stock_Financing_and_Li

Capital Stock, Financing and Liquidity	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	3	Capital Stock, Financing and Liquidity
	On February 18, 2015 the Company closed an underwritten public offering of 2,070,000 registered shares of its common stock, at a price to the public of $1.75 per share, and 695,857 registered shares of its $0.01 par Series B Convertible Preferred Stock (“Series B”) at a price to the public of $8.75 per share. The Series B is convertible into five shares of common stock at the option of the holder, subject to certain limitations related to the holder’s ownership percentage of the Company’s outstanding common stock. The Series B will vote with the common stock on all matters on an as-converted basis, and has no preference to the common shares in respect of dividends, voting, liquidation or otherwise. Gross proceeds from the offering were $9.7 million and underwriters’ fees and issuance costs totaled $1.1 million. Thus, the Company generated net proceeds of $8.6 million from the underwritten public offering.
	The Company has incurred net losses of $34.9 million since inception through March 31, 2015. The Company is currently investing significant resources in development and commercialization of products for use in the field of regenerative medicine. The Company expects to continue to incur operating losses and negative cash flows from operations. Management believes that the Company’s cash at March 31, 2015 will be sufficient to meet the Company’s obligations for at least the next twelve months based on management’s current business plans.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	4	Related Party Transactions
	Harvard Bioscience is considered to be a related party to the Company because David Green, the Company’s former Chairman and CEO was the Chairman and CEO during the periods presented, is also a director of Harvard Bioscience.
	Agreements with Harvard Bioscience
	In connection with the Separation of the Company from Harvard Bioscience, on October 31, 2013 the Company entered into a series of agreements with Harvard Bioscience, including a separation and distribution agreement, a transition services agreement, a tax sharing agreement, a sublicense agreement, a product distribution agreement, an intellectual property matters agreement and a sublease agreement. Some of these agreements require the Company to pay fees to Harvard Bioscience for services provided subsequent to the Separation. The transition services agreement expired on November 1, 2014. Expenses recorded under these agreements were $42,000 and $100,000 for the three months ended March 31, 2015 and 2014, respectively.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2015
Concentrations Disclosure [Abstract]
Concentrations Disclosure [Text Block]	5	Concentrations
	At the time of the Separation, the Company entered into a 10-year product distribution agreement with Harvard Bioscience under which each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other. In addition, Harvard Bioscience has agreed that except for certain existing activities of its German subsidiary, to the extent that any Harvard Bioscience businesses desire to resell or distribute any bioreactor that is then manufactured by HART, HART will be the exclusive manufacturer of such bioreactors and Harvard Bioscience will purchase such bioreactors from the Company. Sales to Harvard Bioscience accounted for 100% of the Company’s revenues and related party receivables.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Share-based Compensation [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6	Stock-Based Compensation
	HART maintains the 2013 Equity Incentive Plan (the “2013 Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the 2013 Plan consist of shares of HART common stock. Additionally, equity awards related to shares of the Company’s common stock were issued from the 2013 Plan at the time of the Distribution to the holders of Harvard Bioscience equity awards as part of an adjustment (the “Adjustment”) to those equity awards to prevent a loss of value to the holders due to the Distribution.
	Harvard Bioscience award holders were also issued stock-based compensation awards in HART stock options and restricted stock units. HART recognizes compensation expense on those awards to former Harvard Bioscience employees who now are employed by HART, and does not recognize expense on the Adjustment awards given to individuals not now employed by HART. Additionally, HART records expense on grants made under the 2013 Plan to HART officers, directors and employees granted subsequent to the Adjustment.
	Harvard Bioscience maintains the Third Amended and Restated 2000 Stock Option and Incentive Plan, (as amended, the “Harvard Bioscience Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the Harvard Bioscience Plan consist of shares of Harvard Bioscience common stock. HART continues to record the expense on stock-based awards of Harvard Bioscience stock options and restricted stock units, issued by Harvard Bioscience, to former Harvard Bioscience employees now employed by HART.
	Harvard Apparatus Regenerative Technology, Inc. 2013 Equity Incentive Plan
	The 2013 Plan was adopted by the Board of Directors on October 11, 2013. The aggregate number of shares authorized for issuance under the Plan is 3,640,000 shares of common stock. The Company currently has 3,640,000 shares of its common stock reserved for the issuance, exercise or vesting of awards under the 2013 Plan. During the three months ended March 31, 2015, all options granted under the 2013 Plan were at exercise prices equal to or greater than fair market value of the Company’s common stock on the date of grant.
	The following is a summary of stock option and restricted stock unit activity for the three months ended March 31, 2015:
			Stock Options					Restricted Stock Units
			Stock Options			Weighted Average		Restricted Stock Units		Grant Date
			Outstanding			Exercise Price		Outstanding		Fair Value
	Balance at December 31, 2014			2,006,980		$	4.73		7,980	$	6
	Granted			449,000			3.99		-		-
	Exercised			-			-		-		-
	Vested (RSUs)			-			-		-3,728		6
	Cancelled/forfeited			-20,277			4.3		-		-
	Balance at March 31, 2015			2,435,703		$	4.6		4,252	$	6
	The following assumptions were used to estimate the fair value of stock options granted during the three months ended March 31, 2015:
			Three Months
			Ended March 31,
			2015
	Volatility			81	%
	Risk-free interest rate			1.77	%
	Expected holding period			6.25 years
	Dividend Yield			-	%
	The weighted average fair value of the options granted under the 2013 Plan during the three months ended March 31, 2015 was $2.81, using the Black-Scholes option-pricing model.
	Stock-based compensation expense for the three months ended March 31, 2015 and 2014, respectively, was allocated as follows:
			Three Months Ended March 31,
			2015			2014
			(in thousands)
	Research and development		$	221		$	287
	Sales and marketing			40			65
	General and administrative			374			642
	Total stock-based compensation		$	635		$	994
	The Company did not capitalize any stock-based compensation related to the 2013 Plan.
	Harvard Bioscience Plan Award Information
	The following is a summary of stock option and restricted stock unit activity for the three months ended March 31, 2015:
			Stock Options					Restricted Stock Units
			Stock Options			Weighted		Restricted Stock		Grant Date
			Outstanding			Average Exercise		Units Outstanding		Fair Value
						Price
	Balance at December 31, 2014			2,122,648		$	2.84		171,557	$	4.41
	Granted			-			-		-		-
	Exercised			-913,707			2.73		-		-
	Vested (RSUs)			-			-		-88,648		4.52
	Cancelled/forfeited			-6,585			3.64		-		-
	Balance at March 31, 2015			1,202,356		$	2.93		82,909	$	4.3
	Stock-based compensation expense from the Harvard Bioscience Plan for the three months ended March 31, 2015 and 2014, respectively, was allocated as follows:
			Three Months Ended March 31,
			2015			2014
			(in thousands)
	Research and development		$	10		$	20
	Sales and marketing			3			3
	General and administrative			90			159
	Total stock-based compensation		$	103		$	182
	The Company did not capitalize any stock-based compensation related to the Harvard Bioscience Plan

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7	Commitments and Contingencies
	From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that the Company expects to be material in relation to its business, financial condition, and results of operations or cash flows.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	8	Subsequent  Events
	In April 2015, David Green resigned as Chief Executive Officer, President and Chairman of the Board of Directors of HART. Mr. Green remained a member of the Board of Directors. HART’s Board of Directors appointed Tom McNaughton, the Company’s Chief Financial Officer, as interim Chief Executive Officer. In addition, John Kennedy, a member of the Company’s Board of Directors since May 2012, was named Chairman of the Board of Directors.
	Under the terms of Mr. Green’s employment agreement, certain equity awards immediately vested upon his resignation. This acceleration of vesting will result in a non-cash stock based compensation expense of approximately $1.0 million being recognized in April, 2015.  Mr. Green’s employment agreement also entitled him to a cash payment equal to two years of his salary, or approximately $1.0 million.  The Company and Mr. Green agreed to a modification to accelerate vesting on certain options and extend the exercise period on those and other vested stock options in lieu of the cash payment. These modifications will result in an additional final non-cash stock based compensation expense related to Mr. Green of approximately $1.1 million being recorded in April, 2015.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Based Compensation [Line Items]
Schedule of Share-based Compensation, Activity [Table Text Block]	The following assumptions were used to estimate the fair value of stock options granted during the three months ended March 31, 2015:
		Three Months
		Ended March 31,
		2015
	Volatility		81	%
	Risk-free interest rate		1.77	%
	Expected holding period		6.25 years
	Dividend Yield		-	%
Harvard Bioscience Plan [Member]
Stock Based Compensation [Line Items]
Schedule of Share-based Compensation, Activity [Table Text Block]	The following is a summary of stock option and restricted stock unit activity for the three months ended March 31, 2015:
		Stock Options					Restricted Stock Units
		Stock Options			Weighted		Restricted Stock		Grant Date
		Outstanding			Average Exercise		Units Outstanding		Fair Value
					Price
	Balance at December 31, 2014		2,122,648		$	2.84		171,557	$	4.41
	Granted		-			-		-		-
	Exercised		-913,707			2.73		-		-
	Vested (RSUs)		-			-		-88,648		4.52
	Cancelled/forfeited		-6,585			3.64		-		-
	Balance at March 31, 2015		1,202,356		$	2.93		82,909	$	4.3
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense from the Harvard Bioscience Plan for the three months ended March 31, 2015 and 2014, respectively, was allocated as follows:
		Three Months Ended March 31,
		2015			2014
		(in thousands)
	Research and development	$	10		$	20
	Sales and marketing		3			3
	General and administrative		90			159
	Total stock-based compensation	$	103		$	182
Equity Incentive Plan 2013 [Member]
Stock Based Compensation [Line Items]
Schedule of Share-based Compensation, Activity [Table Text Block]	The following is a summary of stock option and restricted stock unit activity for the three months ended March 31, 2015:
		Stock Options					Restricted Stock Units
		Stock Options			Weighted Average		Restricted Stock Units		Grant Date
		Outstanding			Exercise Price		Outstanding		Fair Value
	Balance at December 31, 2014		2,006,980		$	4.73		7,980	$	6
	Granted		449,000			3.99		-		-
	Exercised		-			-		-		-
	Vested (RSUs)		-			-		-3,728		6
	Cancelled/forfeited		-20,277			4.3		-		-
	Balance at March 31, 2015		2,435,703		$	4.6		4,252	$	6
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense for the three months ended March 31, 2015 and 2014, respectively, was allocated as follows:
		Three Months Ended March 31,
		2015			2014
		(in thousands)
	Research and development	$	221		$	287
	Sales and marketing		40			65
	General and administrative		374			642
	Total stock-based compensation	$	635		$	994

Overview_and_Basis_of_Presenta1

Overview and Basis of Presentation (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Overview And Basis Of Presentation [Line Items]
Proceeds from Contributions from Parent	$15

Capital_Stock_Financing_and_Li1

Capital Stock, Financing and Liquidity (Details Textual) (USD $)	1 Months Ended	3 Months Ended
	Feb. 18, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Common Stock, Shares, Issued		10,069,676		7,856,607
Payments of Stock Issuance Costs	$1,100,000
Proceeds from Issuance or Sale of Equity	9,700,000
Net Income (Loss) Attributable to Parent, Total		-2,623,000	-3,006,000
Proceeds From Issuance Of Stock To Underwriters	8,600,000
Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued	2,070,000
Shares Issued, Price Per Share	$1.75
Net Income (Loss) Attributable to Parent, Total		$34,900,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Reserved for Future Issuance	695,857
Shares Issued, Price Per Share	$8.75
Preferred Stock, Par or Stated Value Per Share		$0.01

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (Transition Services Agreement [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Transition Services Agreement [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense	$42,000	$100,000

Concentrations_Details_Textual

Concentrations (Details Textual) (Accounts Receivable [Member])	3 Months Ended
	Mar. 31, 2015
Accounts Receivable [Member]
Concentrations Disclosure [Line Items]
Percentage Of Revenue And Receivables From Related Parties	100.00%

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Harvard Bioscience Plan [Member]
Share Based Compensation Activity [Line Items]
Stock Options Outstanding, Balance	2,122,648
Stock Options Outstanding, Granted	0
Stock Options Outstanding, Exercised	-913,707
Stock Options Outstanding, Cancelled / forfeited	-6,585
Stock Options Outstanding, Balance	1,202,356
Weighted Average Exercise Price, Balance	$2.84
Weighted Average Exercise Price, Granted	$0
Weighted Average Exercise Price, Exercised	$2.73
Weighted Average Exercise Price, Cancelled / forfeited	$3.64
Weighted Average Exercise Price, Balance	$2.93
Equity Incentive Plan 2013 [Member]
Share Based Compensation Activity [Line Items]
Stock Options Outstanding, Balance	2,006,980
Stock Options Outstanding, Granted	449,000
Stock Options Outstanding, Exercised	0
Stock Options Outstanding, Cancelled / forfeited	-20,277
Stock Options Outstanding, Balance	2,435,703
Weighted Average Exercise Price, Balance	$4.73
Weighted Average Exercise Price, Granted	$3.99
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Cancelled / forfeited	$4.30
Weighted Average Exercise Price, Balance	$4.60
Restricted Stock Units (RSUs) [Member] | Harvard Bioscience Plan [Member]
Share Based Compensation Activity [Line Items]
Restricted Stock Units Outstanding, Balance	171,557
Restricted Stock Units Outstanding, Granted	0
Restricted Stock Units Outstanding, Exercised	0
Restricted Stock Units Outstanding, Vested (RSUs)	-88,648
Restricted Stock Units Outstanding, Cancelled / forfeited	0
Restricted Stock Units Outstanding, Balance	82,909
GrantDate Fair Value, Balance	$4.41
GrantDate Fair Value, Granted	$0
GrantDate Fair Value, Vested (RSUs)	$4.52
GrantDate Fair Value, Cancelled / forfeited	$0
GrantDate Fair Value, Balance	$4.30
Restricted Stock Units (RSUs) [Member] | Equity Incentive Plan 2013 [Member]
Share Based Compensation Activity [Line Items]
Restricted Stock Units Outstanding, Balance	7,980
Restricted Stock Units Outstanding, Granted	0
Restricted Stock Units Outstanding, Exercised	0
Restricted Stock Units Outstanding, Vested (RSUs)	-3,728
Restricted Stock Units Outstanding, Cancelled / forfeited	0
Restricted Stock Units Outstanding, Balance	4,252
GrantDate Fair Value, Balance	$6
GrantDate Fair Value, Granted	$0
GrantDate Fair Value, Vested (RSUs)	$6
GrantDate Fair Value, Cancelled / forfeited	$0
GrantDate Fair Value, Balance	$6

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Harvard Bioscience Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$103	$182
Equity Incentive Plan 2013 [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	635	994
Selling and Marketing [Member] | Harvard Bioscience Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	3	3
Selling and Marketing [Member] | Equity Incentive Plan 2013 [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	40	65
General and Administrative [Member] | Harvard Bioscience Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	90	159
General and Administrative [Member] | Equity Incentive Plan 2013 [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	374	642
Research and Development [Member] | Harvard Bioscience Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	10	20
Research and Development [Member] | Equity Incentive Plan 2013 [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$221	$287

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (Equity Incentive Plan 2013 [Member])	3 Months Ended
	Mar. 31, 2015
Equity Incentive Plan 2013 [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Volatility	81.00%
Risk-free interest rate	1.77%
Expected holding period	6 years 3 months
Dividend yield	0.00%

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (Equity Incentive Plan 2013 [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Equity Incentive Plan 2013 [Member]
Stock Based Compensation [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$2.81
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,640,000
Common Stock, Capital Shares Reserved for Future Issuance	3,640,000

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2015
Subsequent Event [Line Items]
Employment Agreement Description	Mr. Greens employment agreement also entitled him to a cash payment equal to two years of his salary, or approximately $1.0 million.
Mr.Green [Member]
Subsequent Event [Line Items]
Allocated Share-based Compensation Expense	1,000
Parent Company [Member] | Mr.Green [Member]
Subsequent Event [Line Items]
Allocated Share-based Compensation Expense	1,100